- Sobi® receives positive CHMP opinion recommending approval of efanesoctocog alfa for once-weekly treatment of haemophilia A
- Sobi Q1 2024 report: Strong sales reflecting the strength of the portfolio
- Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)
- Sobi publishes Annual and sustainability report for 2023
Key statistics
On Wednesday, Swedish Orphan Biovitrum AB (publ) (SOBI:STO) closed at 287.80, -4.70% below its 52-week high of 302.00, set on Feb 01, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 284.20 |
---|---|
High | 289.60 |
Low | 283.80 |
Bid | 287.80 |
Offer | 287.80 |
Previous close | 283.40 |
Average volume | 420.39k |
---|---|
Shares outstanding | 354.36m |
Free float | 195.56m |
P/E (TTM) | 45.82 |
Market cap | 100.50bn SEK |
EPS (TTM) | 6.19 SEK |
Data delayed at least 15 minutes, as of May 15 2024 17:00 BST.
More ▼